Anti-Cancer Drug Design

anticancer, pancratistatin, phosphate prodrugs, phosphorylation
pp. 389-395(7)
Authors: Pettit G.; Orr B.; Ducki S.

cation salts, combretastatin A-3, diphosphate, prodrugs
pp. 397-403(7)
Authors: Pettit R.; Minardi D.; Boyd R.; Pettit K.

Synthesis, characterization and cytotoxicity of lanthanum(III) complexes with novel 1,10-phenanthroline-2,9-bis-[agr]-amino acid conjugates
pp. 405-411(7)
Authors: Z-Wang Z-M.; H-Lin H-K.; S-Zhu S-R.; T-Liu T-F.; Z-Zhou Z-F.; Y-Chen Y-T.

etoposide, amsacrine, topoisomerase II, DNA cleavage, cytotoxicity, antitumour drugs
pp. 413-421(9)
Authors: Arimondo P.; Boukarim C.; Bailly C.; Dauzonne D.; Monneret C.

antisense oligonucleotides, mdm2, p53, apoptosis
pp. 423-430(8)
Authors: Geiger T.; Hüsken D.; Weiler J.; Natt F.; Woods-Cook A.; Hall J.; Fabbro D.

thiols, exchange, drug delivery, selectivity
pp. 431-439(9)
Authors: Ross A.; Carr A.; J-Brïet J-W.; Lowe G.

Bcl-2, conformation, loop, model, paclitaxel, phosphorylation
pp. 441-446(6)
Authors: Wu H.; Batist G.

CDK1, cytotoxicity, indoles, imidazothiazoles
pp. 447-452(6)
Authors: Andreani A.; Cavalli A.; Granaiola M.; Leoni A.; Locatelli A.; Morigi R.; Rambaldi M.; Recanatini M.; Garnier M.; Meijer L.

anticancer drug, dibenzodioxin, oxanthrene, tricyclic carboxamide
pp. 453-458(6)
Authors: Spicer A.; Denny A.